Significance Statement {#s5}
======================

Plasma nervonic acid levels were increased in patients with major depressive disorder (MDD) compared with those in patients with bipolar disorder and healthy controls. Nervonic acid levels were higher in the depressive state in the patients with MDD compared with the remission state in the patients with MDD and the depressive state of patients with bipolar disorder, suggesting state-dependent alterations. Therefore, plasma nervonic acid is a good candidate diagnostic biomarker for MDD.

Introduction {#s6}
============

Although a proper diagnosis and medical treatment are important for improving the prognosis of patients with mental illness ([@CIT0035]; [@CIT0016]), diagnoses are difficult to make, especially when major depressive disorder (MDD) needs to be distinguished from the depressive state of bipolar disorder (BD). In addition, patients with schizophrenia (SZ) can also show depressive symptoms. Because treatment approaches differ among patients with MDD, BD, and SZ, diagnostic biomarkers that distinguish MDD, BD, and SZ are required to avoid misdiagnosis ([@CIT0002]) and obtain a better prognosis ([@CIT0013]). Although candidate biomarkers have been studied in various ways ([@CIT0039]), the results of previous studies lack reproducibility, sensitivity, and selectivity ([@CIT0026]; [@CIT0007]).

The plasma levels of hydrophobic molecules, such as steroids and unsaturated fatty acids, have been studied as candidate biomarkers of MDD ([@CIT0019]; [@CIT0029]), BD ([@CIT0010]; [@CIT0031]; [@CIT0041]), and/or SZ ([@CIT0034]; [@CIT0037]; [@CIT0015]; [@CIT0031]; [@CIT0005]). However, these candidate molecules were examined in patients taking medication, and the potential effects of medication cannot therefore be excluded.

In the present study, we performed a comprehensive metabolome analysis using liquid chromatography time-of-flight mass spectrometry (LC-TOFMS) to investigate the use of nonpolar or medium-polar metabolites as biomarkers in plasma samples of drug-free patients with MDD, BD, and SZ. The reproducibility of the results and the effects of psychotropic medication on nervonic acid, which was the most significantly altered metabolite, were verified in an independent sample set of mostly medicated patients. Here, we report that the levels of nervonic acid were increased in patients with MDD in 2 independent sample sets.

Materials and Methods {#s7}
=====================

Participants {#s8}
------------

Cohort 1 of the samples used for LC-TOFMS \[MDD (n=9), BD (n=6), SZ (n=17)\] and matched healthy controls (n=19) was derived from the National Center of Neurology and Psychiatry (NCNP) Biobank (project no. NCNPBB-0002). The patients in cohort 1 had not taken any antipsychotic or antidepressant medications for at least 2 weeks. To measure the absolute concentrations of nervonic acid in cohort 1, gas chromatography TOFMS (GC-TOFMS) was performed, but only 30 samples \[MDD (n=6), BD (n=4), SZ (n=13)\] and controls (n=7) of the 51 samples of cohort 1 from the NCNP Biobank were available. A second cohort of samples \[MDD (n=45), BD (n=71), SZ (n=115)\] and controls (n=90) was obtained from the NCNP Biobank (project no. NCNPBB-0002-1). Cohort 2 also contained samples from Osaka City University Hospital and Hannan Hospital, where controls were recruited from among the healthy spouses of the patients. The control samples in the NCNP Biobank were collected by advertising in local free magazines and on websites.

The sex ratios and ages did not significantly differ among the groups in cohort 1 ([Table 1](#T1){ref-type="table"}). Among the groups in cohort 2, the sex ratios did not significantly differ, while age did ([Table 2](#T2){ref-type="table"}). The age of participants in the MDD and control groups was higher than that of SZ (*P*=.000046 and .000004, respectively). ANCOVA was used for the analysis of age.

###### 

Demographic and Clinical Data for the Participants in Cohort 1

                                                   SZ          MDD         BD          Control     Statistics
  ------------------------------------------------ ----------- ----------- ----------- ----------- ----------------
  Number (male/female)                             17 (8/9)    9 (3/6)     6 (1/5)     19 (10/9)   *P=*.41 ^*a*^
  Age, years (mean±SD)                             33.6±15.7   39.1±10.2   41.8±13.3   36.1±12.9   *P*=.57 ^*b*^
  Duration of illness, years (mean±SD) ^*c*^       9.1±13.7    4.8±2.9     7.8±6.3     N.A.        *P* =.81 ^*b*^
  HAMD-21, score (mean±SD)                         N.A.        11.2±8.5    14.4±5.9    N.A.        N.A
  PANSS positive, score (mean±SD) ^*d*^            21.4±5.4    N.A.        N.A.        N.A.        N.A.
  PANSS negative, score (mean±SD) ^*d*^            22.4±6.4    N.A.        N.A.        N.A.        N.A.
  PANSS general pathology, score (mean±SD) ^*d*^   47.3±11.4   N.A.        N.A.        N.A.        N.A.
  YMRS, score (mean±SD)                            N.A.        N.A.        6.3±4.0     N.A.        N.A.

Abbreviations: BD, bipolar disorder; HAMD-21, 21-item Hamilton Depression Rating Scale; MDD, major depressive disorder; N.A., not applicable; PANSS, Positive and Negative Symptom Scale; SZ, schizophrenia; YMRS, Young Mania Rating Scale.

^*a*^Chi-squared test.

^*b*^ANOVA.

^*c*^Missing data for 5 individuals in the MDD patient group and 1 individual in the BD patient group.

^*d*^Missing data for 4 individuals in the SZ patient group.

###### 

Demographic and Clinical Data for the Participants in Cohort 2

                                               SZ            MDD          BD           Control      Statistics
  -------------------------------------------- ------------- ------------ ------------ ------------ -------------------
  Number (male/female)                         115 (59/56)   45 (19/26)   71 (37/34)   90 (46/54)   *P*=.72 ^*a*^
  Age, years (mean±SD)                         39.0±13.6     50.4±16.0    45.2±13.3    49.2±15.0    *P*=.000046 ^*b*^
  Number of drug-free patients (male/female)   7 (5/2)       4 (3/1)      0            N.A.         N.A.
  Number of patients with depressed state      N.A.          34           25           N.A.         N.A.
  Number of patients with remitted state       N.A.          11           34           N.A.         N.A.
  Number of patients with manic state          N.A.          N.A.         12           N.A.         N.A.
  HAMD-21, score (mean ±SD)                    N.A.          17.0±8.6     9.2±8.1      N.A.         N.A
  PANSS positive, score (mean ±SD)             17.7±5.6      N.A.         N.A.         N.A.         N.A.
  PANSS negative, score (mean±SD)              18.7±6.2      N.A.         N.A.         N.A.         N.A.
  PANSS general pathology, score (mean ±SD)    36.0±8.7      N.A.         N.A.         N.A.         N.A.
  YMRS, score (mean ±SD)                       N.A.          N.A.         5.7±7.4      N.A.         N.A.

Abbreviations: BD, bipolar disorder; HAMD-21, 21-item Hamilton Depression Rating Scale; MDD, major depressive disorder; N.A., not applicable; PANSS, Positive and Negative Symptom Scale; SZ, schizophrenia; YMRS, Young Mania Rating Scale.

^*a*^Chi-squared test.

^*b*^ANOVA.

All participants provided written informed consent after the entire study was explained to them. This study was conducted in accordance with the Declaration of Helsinki and approved by the following: the Ethics Committee of NCNP, the Ethics Committee of Hannan Hospital, the Research Ethics Committee of Osaka City University, and Wako First Research Ethics Committee of RIKEN.

Diagnosis and Assessment of Symptoms {#s9}
------------------------------------

Trained psychiatrists or psychologists conducted structured interviews of the participants using a Japanese version of the Mini-International Neuropsychiatric Interview (M.I.N.I.) ([@CIT0038]), and the results were used to make the diagnoses according to the criteria of the DSM-IV ([@CIT0003]). In cohort 2, we divided the patients with MDD into remitted and depressive state based on M.I.N.I. We also divided the patients with BD into manic, remitted, and depressive states based on M.I.N.I. Patients with any comorbid axis I disorders, histories of central nervous system diseases, substance abuse/dependence, or severe head trauma were excluded. Depressive symptoms were assessed using the 21-item Hamilton Depression Rating Scale (HAMD-21) ([@CIT0020]). The Positive and Negative Syndrome Scale (PANSS) ([@CIT0024]) was used to measure the symptom severity of the patients with SZ. The Young Mania Rating Scale (YMRS) ([@CIT0049]) was utilized to measure the severity of the manic episodes in patients with BD.

Plasma Sampling {#s10}
---------------

Blood samples were collected between 9:00 [am]{.smallcaps} and 4:00 [pm]{.smallcaps}with or without overnight fasting. Information on meals was not available and not considered in the statistical analyses. Blood samples were drawn from a peripheral vein, collected in ethylenediaminetetraacetic acid-2Na-containing vacuum blood collection tubes (VENOJECT II, Terumo Corporation), and immediately placed on ice. Within 30 minutes of the blood collection, plasma samples were isolated via centrifugation at 2500×*g* at 4°C for 10 minutes and stored at --80°C until use.

LC-TOFMS Analysis {#s11}
-----------------

Plasma samples (500 µL) were added to 1200 µL of 1% formic acid/acetonitrile containing an internal standard solution (Solution ID: H3304-1002, Human Metabolome Technologies, Inc.) at 0°C. The solution was thoroughly mixed and centrifuged at 2300×*g* and 4°C for 5 minutes. The supernatant was filtered through Hybrid SPE-Phospholipid (product no. 55261-U; Sigma-Aldrich Corporation). The filtrate was desiccated and then dissolved with 80 µL of isopropanol and Milli-Q (1:1, v/v) for the LC-TOFMS analysis. The detection limit was determined at a signal-to-noise ratio\>3. The candidate peaks were assigned a specific metabolite identity based on their *m/z* (±10 ppm) and retention time (±0.5 minutes) determined by TOFMS. The absolute concentrations were not determined, and the relative peak areas were used in the comparisons. The metabolome measurements were conducted at Human Metabolome Technologies, Inc.

GC-TOFMS Analysis {#s12}
-----------------

We measured the levels of nervonic acid using GC-TOFMS according to a protocol described in a previous report ([@CIT0036]) with slight modifications. Oleic acid d9 (2.5 ng) (Avanti Polar Lipids, Inc) was added to each plasma sample (100 µL) as an internal standard. The plasma sample was added to a mixture of 400 µL methanol, 25 µL 1N HCl, and 1000 µL isooctane. The solution was thoroughly mixed and centrifuged at 800×*g* for 2 minutes at room temperature. Next, 920 µL of supernatant (upper organic phase) was dispensed in a conical glass insert for autosampler vials, dried in vacuo, and added to a mixture of 40 µL of pyridine, 40 µL of *N*-(*tert*-butyldimethylsilyl)-*N*-methyl trifluoroacetamide, and 30 µL of acetonitrile to obtain *tert*-butyldimethylsilyl (TBDMS) esters from the free fatty acids. The sample solutions were placed in sealed autosampler vials, vortexed, and maintained at 60°C for at least 60 minutes before the analysis. Absolute concentrations were quantified using a series of standards of known concentrations of nervonic acid (Sigma-Aldrich, Japan K.K.) mixed with the internal standard. All other regents were obtained from Wako Pure Chemical Industries, Ltd.

We used a JMS-T100GCV time-of-flight mass spectrometer (JEOL Ltd) equipped with a 7890A GC (Agilent Technologies, Inc.) and 7693 autosampler (Agilent Technologies, Inc.). Each TBDMS-derivatized sample solution was injected (2 µL) in the splitless injection mode up to a temperature of 320°C. We used a Zebron ZB-1 MS column (30 m×0.32 mm id; film thickness 0.25µm, Phenomenex, Inc.). The carrier gas was helium, and it was applied at a constant flow-rate of 1.5 mL/min. The GC oven temperature was maintained at 120°C for 4 minutes, ramped up linearly from 120°C to 360°C at 30°C/min, and then maintained at 360°C for 0.5 minutes. The outlet of the column was directly connected to a 70-eV electron ionization source of the mass spectrometer, with a resolving power \>6000 (typical full width at half-maximum mass resolution, 9000). The typical mass accuracies were \<5 ppm after the application of single-point internal mass drift compensation using the column bleed peak (*m/z*, 281.0517). Peak areas of high-resolution accurate-mass extracted ion chromatograms for the characteristic fragment ions at \[M - 57\]^+^ from TBDMS-derivatized analyte and internal standards were used for quantitation. Examples of chromatograms of nervonic acid (*m/z*, 423.3658±0.005; retention time, 11.50 minutes) and oleic acid d9 (*m/z*, 348.32842±0.005; retention time, 10.00 minutes) are shown in supplementary Figure 1.

Statistical Analysis {#s13}
--------------------

The data are presented as mean±SD. The means were compared using Welch *t* test, 1-way ANOVA followed by posthoc Tukey's test, or Kruskal-Wallis test. Any missing values for the relative area were replaced with *machine epsilon* (≃0). In the full Institute of Electrical and Electronics Engineers system, the spacing was 2×10^-\ 52^. ANCOVA that controlled for age and sex was used to evaluate the effects of age and sex on the nervonic acid levels. Categorical variables were compared using chi-squared test. The threshold for statistical significance was set at *P*\<.05 for all analyses, and multiple comparisons were corrected for using the false discovery rate. Statistical power and effect size were calculated using G-Power version 3.1 ([@CIT0014]). The statistical analyses were conducted using R version 3.2.5 ([https://www. r-project.org/](https://www.r-project.org/)) and IBM Statistical Package for Social Sciences Statistics 23, Japanese version (IBM Japan).

Results {#s14}
=======

Metabolome Analysis in Cohort 1 {#s15}
-------------------------------

The LC-TOFMS metabolome analysis detected 126 candidate peaks in the cohort 1 plasma samples (supplementary Table 1). We used an ANOVA or Kruskal-Wallis test to identify the peaks that significantly differed among the 4 sample groups (MDD, BD, SZ, and controls). A nominally significant effect of diagnosis on the relative peak area was found for 2 peaks, which were assigned to cortisone (*F*=2.851, *P=*.047, *f*=0.42) and nervonic acid (*χ*^2^=13.41, *P=*.0038). A nominally significant increase was found in cortisone, a precursor of cortisol, in patients with SZ compared with controls (*P=*.048) ([Figure 1a](#F1){ref-type="fig"}). None of these differences were statistically significant after correcting for multiple comparisons. For nervonic acid, a Kruskal-Wallis test showed nominally significant effect of diagnosis. However, over one-half of the nervonic acid measures were below the detection limit of LC-TOFMS. To determine the groups that showed significantly different levels of nervonic acid, we reanalyzed the samples for nervonic acid using GC-TOFMS, which is more sensitive than LC-TOFMS, to obtain more precise data. We measured the absolute concentrations of plasma nervonic acid in the 30 available samples \[MDD (n=6), BD (n=4), SZ (n=13)\] and controls (n=7) of the 51 subjects of cohort 1. We were not able to measure the nervonic acid in the remaining 21 subjects, because sufficient sample volumes were not available. We detected plasma nervonic acid in all 30 samples. The inter-assay CV for nervonic acid (n=12) was 9.2%. Patients with MDD had significantly increased levels of nervonic acid (0.62±0.20 µM) compared with controls (0.29±0.053 µM, *P=*.005) and patients with BD (0.35±0.17 µM, *P=*.049) ([Figure 1b](#F1){ref-type="fig"}). To evaluate the effects of potential confounding factors on the plasma levels of nervonic acid, we applied an ANCOVA with a dependent variable of the metabolite levels, an independent variable of diagnosis, and the covariates of age and sex. The effects of diagnosis on the nervonic acid levels remained significant (*P=*.009). The nervonic acid levels were not significantly correlated with age (*P=*.082) or sex (*P=*.42).

![Plasma level of metabolites with significant differences in the cohort 1 samples. The bars indicate the mean of each group. The error bars represent the SDs. Comparison of the plasma levels of metabolites among the patients with schizophrenia (SZ), major depressive disorder (MDD), and bipolar disorder (BD), and healthy controls (1-way ANOVA with posthoc Tukey's test). (a) Cortisone was measured using liquid chromatography time-of-flight mass spectrometry (LC-TOFMS) in 51 samples. The Y-axis shows the relative concentrations. (b) The levels of nervonic acid were measured using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) in the 30 available samples of cohort 1. The y-axis shows the absolute concentrations. The data on the relative concentrations of nervonic acid are listed in supplementary Table 1.](pyx08901){#F1}

Increased Levels of Nervonic Acid Level in Patients with MDD {#s16}
------------------------------------------------------------

We focused on nervonic acid, because it was the most significantly altered metabolite (*P=*.005, *f*=0.78). We confirmed the reproducibility of the results in the medicated condition and the effects of psychotropic medication on nervonic acid by measuring the levels of nervonic acid using GC-TOFMS in an independent sample set. We performed a power analysis to determine the sample size required to replicate the initial nervonic acid finding with reasonable statistical power at an alpha value of 0.05, (1 -- β) of 0.80, and an effect size of *f*=0.2. Because the sample conditions differed between the sets (cohort 1, drug-free; cohort 2, mostly medicated), we estimated that the effect size would be relatively small. The total number of samples required to attain sufficient statistical power to detect a difference was n=280. We measured 321 samples of mostly medicated patients or controls (MDD, n=45; BD, n=71; SZ, n=115; control, n=90) ([Table 2](#T2){ref-type="table"}). Similar to the results obtained for cohort 1, patients with MDD in cohort 2 had significantly increased plasma nervonic acid levels (0.59±0.41 µM) compared with controls (0.40±0.29 µM; *P=*.0022), patients with BD (0.39±0.25 µM; *P=*.0013), and patients with SZ (0.44±0.24 µM; *P=*.021) ([Figure 2](#F2){ref-type="fig"}). The effect size was *f*=0.26. The sensitivity and specificity of the plasma nervonic acid levels that discriminated between patients with MDD and controls were 67.1% and 62.2%, respectively. To evaluate the effects of the confounding factors on the plasma levels of nervonic acid, we applied an ANCOVA with a dependent variable of the metabolite levels, an independent variable of diagnosis, and the covariates of age and sex. The effects of diagnosis on the nervonic acid levels remained significant (*P=*.0016), although the levels of nervonic acid were affected by age (*P=*.010).

![Absolute plasma levels of nervonic acid in the cohort 2 samples. The bars indicate the mean of each group. The error bars represent the SDs. Comparison of the absolute plasma levels of nervonic acid among the patients with schizophrenia (SZ), major depressive disorder (MDD), bipolar disorder (BD), and healthy controls (1-way ANOVA with posthoc Tukey's test).](pyx08902){#F2}

Relationship between Nervonic Acid Levels and the Clinical Assessments {#s17}
----------------------------------------------------------------------

To determine whether the levels of nervonic acid changed in a state-dependent manner in patients with MDD, we divided the patients with MDD into the following 2 groups based on the M.I.N.I. results: depressed (dMDD) patients (n=34) and remitted (rMDD) patients (n=11) (supplementary Table 2). The levels of nervonic acid were higher in the dMDD patients (0.65±0.45 µM) compared with the rMDD patients (0.40±0.17 µM; effect size of Cohen's *d*=0.75; *P=*.0091) ([Figure 3a](#F3){ref-type="fig"}).

![State-dependent changes in plasma levels of nervonic acid in patients with MDD and BD in cohort 2. The bars indicate the mean for each group. The error bars represent the SDs. (a) Comparison between patients in the depressive state of major depressive disorder (dMDD) and the remitted state of major depressive disorder (rMDD) (Welch *t* test). (b) Comparison among patients in the depressive state of bipolar disorder (dBD), the remitted state of bipolar disorder (rBD), and the manic state of bipolar disorder (mBD) (1-way ANOVA with posthoc Tukey's test). (c) Comparison between patients with dMDD and dBD (Welch *t* test). (d) Comparison between patients with rMDD and rBD (Welch *t* test).](pyx08903){#F3}

The patients with BD were divided into the following 3 groups based on the M.I.N.I. results: depressed (dBD) patients (n=25), remitted (rBD) patients (n=34), and manic (mBD) patients (n=12) (supplementary Table 3). No significant state-dependent difference were found in the patients with BD (dBD, 0.44±0.30 µM; rBD, 0.32±0.17 µM; mBD, 0.46±0.31 µM; *f*=0.57, *P=*.09) ([Figure 3b](#F3){ref-type="fig"}). We compared the plasma levels of nervonic acid in the dMDD and dBD patients (supplementary Table 4) and found that the dMDD patients had increased plasma nervonic acid levels compared with those in the dBD patients (*d*=0.54, *P=*.038) ([Figure 3c](#F3){ref-type="fig"}). The plasma nervonic acid levels did not significantly differ between the rMDD and rBD patients (*d*=0.47, *P=*.20) ([Figure 3d](#F3){ref-type="fig"}; supplementary Table 5).

We then investigated the relationships among the symptoms of the patients (PANSS positive, negative, or general pathology scores; YMRS scores; and HAM-D21 scores), duration of illness, and nervonic acid levels with correlation analyses using Spearman's rank correlation coefficients. There were no significant correlations between nervonic acid levels and the clinical scores. However, the nervonic acid concentrations positively correlated with the duration of illness in the patients with MDD (*ρ*=0.55, *P=*.0011).

Discussion {#s18}
==========

To the best of our knowledge, this is the first study to examine plasma nervonic acid as a potential biomarker of MDD. Because the profile of plasma metabolites might be potentially affected by antipsychotic ([@CIT0008]) and antidepressant drugs ([@CIT0046]), we investigated candidate metabolites in a drug-free sample set of patients, who were not currently on medication, to avoid detection of metabolites that are affected by medication. Subsequently, we confirmed that the levels of plasma nervonic acid were altered in an independent sample set of patients who were mostly medicated.

Nervonic acid \[(Z)-Tetracos-15-enoic acid or 24:1, *n*-9 by the International Union of Pure and Applied Chemistry nomenclature\] is a long chain of monounsaturated omega-9 fatty acids that are particularly abundant in the white matter of the brain. Nervonic acid is an essential molecule for the growth and maintenance of the brain and peripheral nervous tissue enriched in sphingomyelin ([@CIT0030]) and related to psychiatric disorders ([@CIT0004]). Because sphingomyelin is a key constituent of myelin, it is abundant in the white matter of the brain. Our results showed that plasma nervonic acid levels were increased in patients with MDD, in whom the integrity of the white matter has been reported as impaired ([@CIT0033]; [@CIT0028]). Thus, increased levels of plasma nervonic acid might reflect white matter dysfunction in patients with MDD.

White matter dysfunction has also been reported in patients with BD and SZ ([@CIT0042]; [@CIT0040]). Why were the levels of plasma nervonic acid increased only in the patients with MDD? One possibility is that the cause of white matter dysfunction might be different in the patients with MDD compared with the patients with BD and SZ ([@CIT0022]). Whereas sphingomyelin is abundant in myelin-forming oligodendrocytes, it also exists in lipid rafts of neuronal cells, which influence the potency and efficacy of neurotransmitter receptors and transporters. The effects of lipid rafts on neurotransmitter signaling have been implicated in neurological and psychiatric diseases ([@CIT0001]). Sphingomyelin has also been reported to be associated with the regulation of neurogenesis. An association of decreased neurogenesis in the hippocampus and the dysregulation of sphingomyelin metabolic pathway has been suggested to play a role in depression ([@CIT0018]), and antidepressants have been postulated to enhance neurogenesis by inhibiting the acid sphingomyelinase/ceramide system, which is part of the sphingomyelin metabolic pathway ([@CIT0017]). Thus, increased levels of plasma nervonic acid might reflect dysregulation of oligodendrocytes, sphingomyelin-rich lipid rafts, and/or the sphingomyelin metabolic pathway in patients with MDD.

A previous report has shown that the nervonic acid levels that were measured in erythrocyte membranes from patients with recurrent MDD were decreased ([@CIT0006]). This finding might be due to differences in MDD subtype (recurrent vs not recurrent), methodology (LC-TOFMS vs GC-TOFMS), or the types of samples (plasma vs erythrocyte membrane) ([@CIT0021]). In addition, previous studies ([@CIT0006]; [@CIT0029]) have shown that omega-3 and omega-6 polyunsaturated fatty acids are altered in patients with MDD compared with controls. We detected omega-3 and omega-6 polyunsaturated fatty acids (supplemental Table 1), but no significant differences were found between patients with MDD and controls. Because nervonic acid does not cross the blood-brain barrier ([@CIT0011]), it is not clear whether there is a relationship between peripheral nervonic acid levels and its levels in the brain. More studies, including studies of postmortem brains or cerebrospinal fluid, are necessary to fully elucidate the relationship between MDD and nervonic acid.

A previous study ([@CIT0025]) has reported a correlation between erythrocyte nervonic acid and positive symptoms on PANSS in ultra-high-risk subjects. However, plasma nervonic acid levels and PANSS scores were not correlated in the results of the present study, and the difference between the previous findings and our findings might have been due to the differences in the subjects (SZ vs ultra-high-risk subjects) or types of samples (plasma vs erythrocyte membrane).

We calculated the effect sizes to evaluate if plasma nervonic acid levels would be useful as a diagnostic biomarker. The effect size of the nervonic acid level comparisons between the dMDD and rMDD patients (*d*=0.75, [Figure 3a](#F3){ref-type="fig"}) and dMDD and dBD patients (*d*=0.54, [Figure 3c](#F3){ref-type="fig"}) was medium, while the effect size was small in the comparisons among MDD, BD, SZ, and controls (*f*=0.26, [Figure 2](#F2){ref-type="fig"}). These results suggested that nervonic acid levels can be used as a biomarker to discriminate the depressive state of patients with MDD from the euthymic state of patients with MDD or the depressive state of patients with BD. On the other hand, nervonic acid levels would not be useful to discriminate euthymic patients with MDD from controls or patients with other mental disorders (SZ or BD). Additional longitudinal measurements of plasma nervonic acid levels along with detailed information on clinical symptoms in the same individual are required to determine whether nervonic acid levels show state or trait-dependent changes.

Cortisone is a 21-carbon steroid that is one of the main hormones released by the adrenal gland in response to stress ([@CIT0043]). It is converted to the active metabolite hydrocortisone, which is also called cortisol. The results of the current study showed that patients with SZ exhibited increased levels of cortisone. These results may reflect the well-established finding of abnormalities of the hypothalamic-pituitary-adrenal axis in patients with SZ ([@CIT0044]). A previous report has shown that plasma cortisone levels were increased in patients with MDD compared with controls ([@CIT0045]). However, no significant differences were found in this study. The discrepancy of these results might have been a result of differences in methodology (LC-TOFMS vs specific radioimmunoassay) ([@CIT0021]).

This study had several limitations. First, effects of diet ([@CIT0009]; [@CIT0048]), age ([@CIT0023]), circadian variation ([@CIT0012]), and other confounding factors ([@CIT0027]) on the plasma levels of metabolites cannot be excluded. Because we did not strictly control the meal and sample collection time, some of the observed changes might be attributable to these confounding factors. Additional studies involving larger sample size and controlling for all confounding factors are needed to validate the use of plasma nervonic acid levels as a biomarker of MDD. Second, we obtained data only for patients with MDD, BD, and SZ, as well as controls. Additional studies of patients with other neuropsychiatric disorders and demyelinating diseases, such as adrenoleukodystrophy ([@CIT0032]), are necessary to determine if increased levels of plasma nervonic acid level are specific to patients with MDD. Third, the number of participants examined in this study was too small to draw definitive conclusions. Fourth, a confounding effect of metabolic syndrome on plasma nervonic acid cannot be totally ruled out, because a relationship between nervonic acid and metabolic syndrome has been reported ([@CIT0047]). In the 30 samples of cohort 1, a weak tendency for correlation between plasma nervonic acid level and cholesterol level was found (*ρ*=0.32, *P=*.083). Fifth, there was a relatively consistent effect of age on nervonic acid levels (cohort 1, *P=*.082; cohort 2, *P=*.010). Thus, subgroup analyses should be interpreted with caution when the ages between groups are different.

In conclusion, we found that the levels of plasmanervonic acid were increased in patients with MDD. These results suggested that this metabolite would be a good candidate biomarker for the differential diagnosis, depressive state assessment, and treatment optimization of patients with MDD.

Supplementary Material
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

We thank Drs Taku Doi and Mariko Yamada for their help during sample collection. We are grateful to the members of our laboratory for their valuable discussions and technical assistance and to the patients and controls who participated in this study.

Author Contributions {#s19}
====================

T. Kasahara, T. Kato, and Y. Kageyama conceived and designed the study. Y. Kageyama, T. Nakamura, T. Kasahara, and T. Kato acquired and analyzed the data. K. Hattori, S. Yoshida, Y. Goto, K. Inoue, M. Tani, Y. Deguchi, K. Kuroda, and Y. Kageyama collected the human samples and drafted the manuscript. Y. Kageyama, T. Kasahara, and T. Kato wrote the paper.

Funding {#s20}
=======

This work was supported by the Japan Agency for Medical Research and Development (T. Kato: 16815678), MEXT/JSPS KAKENHI grants (T. Kato: 24249063 and 17H01573), and a grant-in-aid from the Japanese Ministry of Health and Labor (T. Kato: 201241002A). Y. Kageyama is supported by a RIKEN Junior Research Associate fellowship.

Statement of Interest {#s21}
=====================

T. Kato has received honoraria for lectures, manuscripts, and/or consultancy from Kyowa Hakko Kirin Co., Ltd.; Eli Lilly Japan K.K.; Otsuka Pharmaceutical Co., Ltd.; GlaxoSmithKline K.K.; Taisho Toyama Pharmaceutical Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; Meiji Seika Pharma Co., Ltd.; Pfizer Japan Inc.; Mochida Pharmaceutical Co., Ltd.; Shionogi & Co., Ltd.; Janssen Pharmaceutical K.K.; Yoshitomiyakuhin; Astellas Pharma Inc.; Wako Pure Chemical Industries, Ltd.; and Takeda Pharmaceutical Co., Ltd. within the last 3 years. T. Kato also received a research grant from Takeda Pharmaceutical Co., Ltd. These companies played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
